Equine Arteritis Virus (EVA)

Equine Viral Arteritis is an infectious disease caused by equine arteritis virus, a member of the Arteriviridae family. This disease affects horses worldwide and is characterized by its ability to cause respiratory illness, widespread vascular damage, and reproductive losses including abortion in pregnant mares and the establishment of a persistent carrier state in infected stallions. The virus has significant economic implications for the horse breeding industry due to its impact on reproduction and international trade restrictions imposed on infected animals.

The prevalence of equine viral arteritis varies considerably between horse populations, breeds, and geographic regions. Serological surveys indicate that Standardbreds and Warmbloods have the highest seroprevalence, while Thoroughbreds historically have much lower infection rates due to breed-specific management and testing requirements. The virus is present globally but with significant regional variations in prevalence. Infected carrier stallions serve as the primary reservoir for the virus, maintaining it in horse populations through venereal transmission.

The impact of equine viral arteritis ranges from subclinical infection to severe clinical disease with significant reproductive consequences. While many infected horses develop only mild illness or remain asymptomatic, the virus can cause abortion storms affecting up to sixty percent of pregnant mares in naive populations exposed to the virus. Young foals and immunocompromised horses may develop severe respiratory disease. The establishment of the carrier state in stallions has major implications for breeding programs and international movement of breeding animals.

Equine viral arteritis is generally self-limiting in most infected horses, with supportive care sufficient for recovery. However, early detection is crucial for implementing appropriate biosecurity measures to prevent spread to susceptible horses, particularly pregnant mares and valuable breeding stock. Vaccination is available and recommended for stallions and horses at risk of exposure. Understanding this disease is essential for breeding farm managers and veterinarians to protect horse populations and maintain compliance with regulatory requirements.

Equine viral arteritis is caused by equine arteritis virus, a small, enveloped RNA virus belonging to the family Arteriviridae. The virus is antigenically homogeneous, meaning there is only one serotype, which has important implications for vaccine development and immunity. Despite antigenic uniformity, genetic variation exists between virus strains, and some strains demonstrate enhanced virulence or greater ability to establish persistent infection in stallions. The virus is relatively fragile in the environment but can persist in cooled or frozen semen for extended periods.

There is no genetic predisposition to equine arteritis virus infection at the individual level, but breed-specific prevalence patterns exist due to historical management practices. Standardbreds have the highest seroprevalence, likely due to the extensive use of artificial insemination with limited testing requirements historically. Warmbloods also show elevated prevalence. Thoroughbreds have maintained low prevalence through strict testing protocols and natural service requirements that limit virus spread. The tendency for stallions to become persistent carriers is the key factor maintaining the virus in horse populations.

Environmental and management factors play crucial roles in equine viral arteritis transmission. The virus spreads through respiratory secretions during acute infection, with aerosol transmission occurring over short distances in enclosed spaces. Venereal transmission from carrier stallions to mares during natural breeding or through infected semen is the primary route for reproductive tract introduction. Vertical transmission from infected mares to fetuses causes abortion. Fomite transmission through contaminated equipment is possible during the acute phase.

Risk factors for equine viral arteritis include breeding mares to stallions of unknown EVA status, introduction of horses from high-prevalence populations, and housing susceptible horses in proximity to acutely infected animals. Stress from transport, competition, or other illness may increase susceptibility. Pregnant mares are at risk for abortion when exposed during gestation. Stallions are at risk for developing the carrier state, particularly if infected as adults and not previously vaccinated.

The pathophysiology of equine arteritis virus involves primary replication in respiratory epithelium and macrophages following inhalation or mucosal exposure. Viremia develops and the virus targets vascular endothelium throughout the body, causing arteritis and increased vascular permeability. Endothelial damage results in edema, particularly affecting the limbs, ventral abdomen, and periorbital tissues. In pregnant mares, placental vasculitis leads to fetal death and abortion. In stallions, the virus establishes persistent infection in the reproductive tract, with continuous shedding in semen maintained by testosterone.

Early warning signs of equine viral arteritis infection include mild fever, subtle depression, and slight decrease in appetite that may be easily overlooked. Some horses develop mild conjunctivitis with watery ocular discharge as an initial sign. The incubation period following respiratory exposure ranges from three to fourteen days, while venereal exposure may produce signs within six to eight days. As horses naturally minimize display of illness, early symptoms require attentive observation to detect, particularly in group housing situations.

Common symptoms of equine viral arteritis center on the respiratory system and characteristic edema formation. Nasal discharge ranges from serous to mucopurulent. Conjunctivitis with marked lacrimation is frequently observed, sometimes with periorbital swelling. Fever typically ranges from thirty-nine to forty-one degrees Celsius. The hallmark physical finding is dependent edema affecting the lower limbs, ventral abdomen, scrotum in stallions, and mammary gland in mares. Skin rash or urticaria develops in some cases.

Behavioral changes in horses with equine viral arteritis include lethargy, depression, and reduced appetite corresponding to fever and general malaise. Stallions may show decreased libido during acute infection. Mares may display signs of abdominal discomfort if abortion is impending. Affected horses often appear stiff and reluctant to move due to limb edema and general discomfort. Some horses display photophobia and keep eyes partially closed due to conjunctival irritation.

Physical signs beyond edema and respiratory involvement include enlarged lymph nodes, particularly the submandibular and retropharyngeal nodes. Respiratory rate may be elevated, though severe respiratory distress is uncommon except in foals. Scrotal edema in stallions can be dramatic and may cause temporary or permanent testicular damage if severe. Pregnant mares may abort without premonitory signs, or may show vaginal discharge indicating impending pregnancy loss.

Symptom progression typically shows peak clinical signs five to seven days following exposure, with gradual improvement over the subsequent one to two weeks. Edema resolves slowly over days to weeks. Fever typically breaks within one week. Horses shed virus in respiratory secretions for seven to fourteen days. Carrier stallions remain clinically normal but continuously shed virus in semen indefinitely unless specifically treated. Abortion may occur from three days to several months post-exposure depending on stage of gestation.

Emergency symptoms requiring immediate veterinary attention include severe respiratory distress in young foals, which can develop fatal pneumonia. Signs of impending abortion in pregnant mares including vaginal discharge, premature udder development, or relaxation of pelvic ligaments warrant urgent evaluation. Severely swollen limbs limiting mobility require attention. Any suspect EVA case in a breeding facility constitutes an emergency due to potential for explosive spread to susceptible animals.

Physical examination of horses with suspected equine viral arteritis reveals characteristic findings that support clinical diagnosis. Veterinarians assess temperature, typically finding fever in acute cases, and note respiratory rate and character. Careful evaluation documents the distribution and severity of edema, particularly in dependent areas. Examination of mucous membranes may reveal congestion or petechiation. Ophthalmic examination assesses conjunctival inflammation. In stallions, scrotal examination documents any swelling or changes suggesting testicular involvement.

Diagnostic tests for equine viral arteritis include virus isolation from nasopharyngeal swabs, conjunctival swabs, or buffy coat samples during acute infection. Polymerase chain reaction testing provides rapid and sensitive detection of viral nucleic acid from clinical samples. Semen samples from stallions allow identification of the carrier state through virus isolation or PCR. Serological testing using virus neutralization assays detects antibodies, with paired samples collected two to three weeks apart demonstrating rising titers diagnostic of recent infection.

Advanced diagnostics focus particularly on stallion evaluation for carrier status due to the reproductive and regulatory implications. Semen evaluation including virus isolation or PCR testing identifies shedding stallions. Test breeding to seronegative mares followed by serological evaluation confirms transmission ability. In aborted fetuses, virus isolation from fetal tissues and placenta provides definitive diagnosis. Histopathological examination reveals characteristic arteritis and vascular lesions. Immunohistochemistry can demonstrate viral antigen in tissues.

Differential diagnosis for horses presenting with fever, respiratory signs, and edema includes equine influenza, which causes more severe respiratory disease without typical EVA edema pattern. Equine herpesvirus infection causes respiratory illness and abortion but less prominent edema. Purpura hemorrhagica produces marked limb edema but following streptococcal infection. African horse sickness in endemic areas causes severe edema and respiratory signs. Immune-mediated conditions and plant toxicoses may cause edema. For abortion cases, equine herpesvirus, leptospirosis, and other infectious causes must be considered.

Emergency and immediate treatment for equine viral arteritis focuses on supportive care, as no specific antiviral therapy exists. Affected horses should be isolated to prevent respiratory transmission to susceptible herdmates. Rest is essential during acute illness. Pregnant mares with potential exposure require close monitoring but may still abort despite intervention. Carrier stallions should be immediately segregated and excluded from breeding until appropriate management decisions are made.

Medical management centers on symptomatic treatment and supportive care. Non-steroidal anti-inflammatory drugs such as flunixin meglumine or phenylbutazone help reduce fever, decrease inflammation, and improve comfort. Diuretics may be considered for severe edema but are generally not necessary as edema resolves with time. Antimicrobial therapy is not indicated for uncomplicated viral disease but may be appropriate if secondary bacterial infection develops. Careful fluid management maintains hydration without exacerbating edema.

There are no surgical interventions specifically indicated for equine viral arteritis. The vascular damage and inflammatory response resolve without surgical treatment. In rare cases, severely swollen limbs might require supportive bandaging. Scrotal edema in stallions is managed medically with cold therapy and support rather than surgically.

Supportive care forms the foundation of treatment for horses with equine viral arteritis. Rest and confinement reduce metabolic demands during acute illness. Maintaining feed and water intake supports recovery. Cold hosing and supportive wrapping of edematous limbs promotes comfort and may accelerate resolution. Protection from temperature extremes reduces physiological stress. Pregnant mares should be kept calm with minimal handling to reduce stress that might precipitate abortion.

Rehabilitation and return to work following equine viral arteritis generally proceeds smoothly once clinical signs resolve, typically within two to three weeks for uncomplicated cases. Horses can gradually return to exercise after fever resolves and edema substantially improves. Athletic horses should be conditioned gradually with attention to any exercise intolerance. Stallions should not resume breeding until the carrier state is definitively ruled out through appropriate testing protocols.

Treatment decisions for carrier stallions present particular challenges given the lifelong nature of infection if untreated. GnRH vaccination or temporary immunosuppression protocols can eliminate the carrier state in some stallions, though these are specialized treatments requiring veterinary expertise. Commercial value, breeding program impact, and regulatory requirements influence management decisions. Some owners elect to retire carrier stallions from breeding rather than pursue elimination attempts.

Recovery timeline for equine viral arteritis in acutely infected horses typically spans two to three weeks for resolution of clinical signs. Fever usually resolves within one week of onset. Edema gradually decreases over one to two weeks, though some residual swelling may persist longer. Respiratory signs clear as the acute phase passes. Most horses are clinically normal within three weeks, though virus shedding continues for seven to fourteen days after symptom resolution. Full return to athletic performance is expected in uncomplicated cases.

Post-treatment care and monitoring following acute EVA infection includes confirmation of complete clinical recovery before returning to work or breeding activities. For stallions, serial semen testing over several weeks confirms either clearance of infection or establishment of the carrier state. Mares that abort should be rested before rebreeding and confirmed serologically for immune status. Horses should remain isolated until respiratory shedding ceases, typically two weeks following recovery. Documentation of infection and recovery is important for future health records and regulatory compliance.

Prognosis factors for equine viral arteritis relate to the specific manifestations in affected horses. Adult horses with typical respiratory and edematous disease have excellent prognosis for complete recovery. Young foals with severe respiratory involvement face more guarded prognosis. Pregnant mares may lose the current pregnancy but typically breed back successfully in subsequent cycles. Stallions face variable prognosis for carrier state development, with vaccination history and age at infection influencing likelihood of becoming persistent shedders.

Long-term soundness outlook for horses recovering from equine viral arteritis is generally excellent. Most horses return to their previous level of performance without lasting effects. However, stallions becoming persistent carriers face significant implications for their breeding careers, with regulatory restrictions and mare owner concerns limiting their commercial use. Severe scrotal edema in stallions occasionally causes permanent testicular damage affecting fertility. Mares that abort typically conceive normally in subsequent breeding seasons.

Management practices for preventing equine viral arteritis center on biosecurity protocols targeting the various transmission routes. Testing stallions for carrier status before use in breeding programs is essential, with seropositive stallions requiring semen testing to determine if they are active shedders. Introduction of new horses should include serological testing and isolation periods. Mares bred to seropositive stallions should be isolated from seronegative pregnant mares for three weeks following breeding. Respiratory transmission prevention requires isolation of acutely infected horses and attention to ventilation and spacing.

Nutritional prevention has no direct role in equine viral arteritis, but maintaining horses in good overall condition supports immune function. Balanced nutrition optimizes the immune response to both infection and vaccination. Horses in appropriate body condition recover more readily from illness. Ensuring adequate colostrum intake by foals born to seropositive mares provides passive antibody protection during the vulnerable early months of life.

Exercise and conditioning practices should avoid excessive stress that might increase susceptibility to infection or complicate recovery if infection occurs. Horses in appropriate fitness for their intended use have better overall disease resistance. During outbreak situations, reduced activity may be appropriate to minimize aerosol generation and transmission risk. Horses recovering from infection should return to work gradually.

Environmental factors influencing EVA prevention include facility design allowing adequate separation between horse groups, particularly isolation facilities for new arrivals and suspect cases. Ventilation systems should minimize shared airspace between different populations. Cleaning and disinfection of shared equipment reduces fomite transmission during outbreaks. Semen collection facilities require careful hygiene protocols given the potential for viral contamination.

Vaccination against equine viral arteritis is available and provides effective protection against clinical disease and abortion. Modified live virus vaccine is highly effective but creates seropositive horses that cannot be distinguished from naturally infected animals without prior testing. Vaccination strategy therefore requires careful planning, with pre-vaccination serology establishing negative baseline status. Colts should be vaccinated before puberty to prevent carrier state development if exposed. Mares should be vaccinated at least three weeks before breeding to seropositive stallions. Annual boosters maintain immunity.

Daily management adjustments for horses on premises with equine viral arteritis require attention to biosecurity and monitoring protocols. Staff should monitor all horses for early signs of illness including fever, nasal discharge, and edema. Separate equipment should be used for seropositive versus seronegative horses where both populations exist on a facility. Hand washing and boot disinfection between handling different groups reduces transmission risk. Pregnant mares require particular attention and should be separated from horses of unknown or positive status.

Housing and turnout considerations reflect the need to manage different serological status groups appropriately. Seropositive horses can be housed together without concern for EVA transmission between them. Seronegative horses, particularly pregnant mares, should be maintained separately with attention to preventing contact with seropositive animals. Carrier stallions require housing arrangements that prevent any possibility of contact with seronegative mares. Ventilation between areas housing different populations should minimize shared airspace.

Exercise modifications during active infection center on rest during the acute febrile phase with gradual return to work as clinical signs resolve. Horses with significant limb edema may be uncomfortable with extensive movement and benefit from limited activity until swelling decreases. Light hand walking can resume once fever resolves. Return to full training should be gradual over one to two weeks following clinical recovery. Carrier stallions can continue normal exercise but should not be used for breeding or housed near breeding mares.

Monitoring and ongoing care for premises affected by equine viral arteritis includes maintaining accurate serological records for all horses. Annual testing of stallions confirms continued carrier status or documents clearance. Mares bred to seropositive stallions should be monitored for seroconversion indicating infection. Pregnant mare populations require monitoring during gestation for any signs of impending abortion. Documentation of vaccination and testing history supports regulatory compliance and informed management decisions.

Quality of life and use considerations for horses with equine viral arteritis are generally favorable given the typically mild and self-limiting nature of clinical disease. Horses recover fully and can continue their intended careers in most cases. Carrier stallions present the greatest management challenge, with commercial breeding careers potentially limited by their status. Some breed registries and importing countries have specific regulations affecting carrier stallions. Decisions about carrier stallion management should consider individual value, regulatory requirements, and practical management capabilities.

Standardbreds have the highest seroprevalence of equine arteritis virus among horse breeds, with surveys indicating thirty to seventy percent seropositive rates in some populations. This elevated prevalence reflects the historical extensive use of artificial insemination in the breed with limited EVA testing requirements. The virus has become endemic in Standardbred populations. Warmbloods also show elevated seroprevalence compared to many other breeds. These breed-specific patterns reflect management practices rather than inherent genetic susceptibility.

Thoroughbreds have maintained notably low equine viral arteritis seroprevalence through breed registry requirements mandating natural cover breeding and extensive testing protocols. The Jockey Club and similar organizations in various countries require EVA testing for stallions, and the natural service requirement eliminates artificial insemination-based transmission routes. This example demonstrates how regulatory and management practices can control disease prevalence within a breed population.

Genetic testing has no role in equine viral arteritis prevention as there is no genetic predisposition to infection or carrier state development. Breeding recommendations focus on testing protocols rather than genetic selection. Stallions should be tested for EVA antibodies and carrier status before entering breeding programs. Seronegative colts intended for breeding should be vaccinated before puberty to prevent carrier state development if later exposed. Mare owners should know the EVA status of stallions used for breeding and make informed decisions about exposure risks.

Commonly co-occurring conditions with equine viral arteritis include secondary bacterial respiratory infections that may develop when viral damage compromises respiratory defenses. Conjunctivitis may become complicated by bacterial infection requiring antimicrobial treatment. In stallions with severe scrotal edema, temporary or permanent reduction in semen quality or fertility may occur. Mares experiencing abortion may develop metritis requiring treatment. Stress-related conditions including gastric ulceration can develop during illness and recovery periods.

Conditions with similar symptoms to equine viral arteritis include other causes of respiratory disease and edema in horses. Equine influenza produces respiratory signs but without the characteristic EVA edema pattern. African horse sickness in endemic areas causes edema and respiratory signs with much higher mortality. Purpura hemorrhagica following streptococcal infection produces dramatic edema. Equine infectious anemia causes intermittent fever and ventral edema. For reproductive losses, equine herpesvirus abortion, leptospirosis, and placentitis must be distinguished from EVA-induced abortion.

Potential complications of equine viral arteritis include abortion storms in naive pregnant mare populations with losses potentially exceeding fifty percent of at-risk pregnancies. Carrier state establishment in stallions creates lifelong management challenges and breeding program impacts. Severe scrotal edema may cause thermal damage to testes with permanent fertility reduction. Young foals may develop severe pneumonia with guarded prognosis. Regulatory consequences including movement restrictions and trade limitations can have significant economic impact beyond direct health effects.